Drug intelligence / Profile preview

LBX242

Development stage: Preclinical
Lead developer: Logix Biosciences
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Intranasal

Overview

LBX242 is a preclinical-stage therapeutic candidate being developed by Logix Biosciences for the treatment of multi-drug-resistant bacterial infections, viral infections, and angiogenic conditions. The asset is being pursued in two distinct forms: a botanical matrix composed of medical-grade Manuka and a synthetic small molecule derivative. Its mechanism of action involves targeted cell wall disruption through a multi-site compositional approach, which is designed to prevent the emergence of evolutionary resistance. According to the developer, this mechanism has shown no observed resistance over two decades of study.

Other names: Botanical Asset

Beyond the preview

Go deeper on LBX242.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LBX242.

Explore the full profile